New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma: Reimbursement Review [Internet].​Pembrolizumab (Keytruda): Indication: In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma: Reimbursement Review [Internet].

By /

Canada’s Drug Agency (CDA-AMC) recommends that Keytruda, in combination with pemetrexed and platinum chemotherapy, be reimbursed by public drug plans for the treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM), if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top